MarketResearchReports.Biz has announced addition of new report "EpiCast Report: Osteoarthritis - Epidemiology Forecast to 2024" to its database.

OA is a degenerative disease of the entire joint, which involves the cartilage, joint lining, ligaments, and underlying bone. OA is the most common form of joint disease. The most affected joints are the knee, hip, hand, and spine. The disease’s onset is gradual and typically seen in middle-aged to elderly people. OA is characterized by pain, stiffness, swelling, crepitus, and limited movement of the affected joint. OA will be the fourth leading cause of disability by the year 2020.

View Full Report at http://www.marketresearchreports.biz/analysis/472255

GlobalData epidemiologists forecast an increase in the total prevalent cases of hand OA in the 7MM from 150,635,612 total prevalent cases in 2014 to 175,213,683 total prevalent cases in 2024 at an AGR of 1.63% during the forecast period. GlobalData epidemiologists forecast that the total prevalent cases of knee OA in the 7MM are expected to increase from 110,840,501 total prevalent cases in 2014 to 127,929,359 total prevalent cases in 2024 at an AGR of 1.54% during the forecast period. GlobalData epidemiologists forecast that the total prevalent cases of hip OA in the 7MM are expected to increase from 61,150,916 total prevalent cases in 2014 to 69,699,696 total prevalent cases in 2024 at an AGR of 1.4% during the forecast period. The diagnosed prevalent cases of hand OA in the 7MM are expected to increase from 61,045,590 diagnosed prevalent cases in 2014 to 70,996,375 diagnosed prevalent cases in 2024 at an AGR of 1.63% during the forecast period. The diagnosed prevalent cases of knee OA in the 7MM are expected to increase from 37,845,305 diagnosed prevalent cases in 2014 to 43,877,213 diagnosed prevalent cases in 2024 at an AGR of 1.59% during the forecast period. The diagnosed prevalent cases of hip OA in the 7MM are expected to increase from 15,116,094 diagnosed prevalent cases in 2014 to 17,276,030 diagnosed prevalent cases in 2024 at an AGR of 1.43% during the forecast period.

Download Sample Copy of this Report at http://www.marketresearchreports.biz/sample/sample/472255

Scope

The Osteoarthritis (OA) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for hand OA, knee OA, and hip OA in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). The report also includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of hand OA, knee OA, and hip OA segmented by age and gender in these markets.
The OA epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

View More latest Reports under Pharmaceutical category at http://www.marketresearchreports.biz/category/38

Reasons to buy

The OA EpiCast series will allow you to

Develop business strategies by understanding the trends shaping and driving the global OA market.
Quantify patient populations in the global OA market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups that present the best opportunities for OA therapeutics in each of the markets covered.


About Us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Read our latest articles at http://www.marketresearchreports.biz/articles


Contact Us

Office: State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: [email protected]